Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 6, 2025 • 5:01 PM ET

Date/Time Source News Release
05/14/2025 04:05 PM EDT GlobeNewswire Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia
05/05/2025 04:05 PM EDT GlobeNewswire Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights
04/01/2025 04:01 PM EDT GlobeNewswire Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03/31/2025 04:10 PM EDT GlobeNewswire Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
03/25/2025 07:00 PM EDT GlobeNewswire Biomea Fusion Announces Leadership Transition
03/24/2025 08:30 AM EDT GlobeNewswire Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose
03/03/2025 08:00 AM EST GlobeNewswire Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
02/27/2025 08:00 AM EST GlobeNewswire Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes
01/13/2025 09:00 AM EST GlobeNewswire Biomea Fusion to Become a Diabetes & Obesity Medicines Company
01/07/2025 09:00 AM EST GlobeNewswire Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
Page